Showing results (1721-1730 of 9,903) with videos related to
Sort By:
Pageof 991
Bone Marrow Transplantation|January 19, 2010
Immunomodulatory effects of vitamin D: implications for GVHDJ Rosenblatt, A Bissonnette, R Ahmad, et al.Bone Marrow Transplantation|December 22, 2009
Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplantC Cordonnier, M Labopin, K U Jansen, et al.Bone Marrow Transplantation|January 12, 2010
Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasiaR P Nelson, M Yu, J E Schwartz, et al.Bone Marrow Transplantation|January 12, 2010
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer studyR Herbrecht, J Maertens, L Baila, et al.Bone Marrow Transplantation|January 12, 2010
Improved outcome in relapsed and refractory myeloid malignancies for unrelated vs related donor allogeneic peripheral blood-derived hematopoietic cell transplantationU Denz, H Bertz, G Ihorst, et al.Bone Marrow Transplantation|January 12, 2010
Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single centerE Carreras, F Fernández-Avilés, L Silva, et al.Bone Marrow Transplantation|January 12, 2010
A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCTM Ando, J Mori, K Ohashi, et al.Bone Marrow Transplantation|December 1, 1993
Interleukin-1 and tumor necrosis factor-alpha as radio- and chemoprotectors of bone marrowS R Dalmau, C S Freitas, D G TabakBone Marrow Transplantation|December 1, 1993
Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivorsJ M Bird, N H Russell, D SamsonBone Marrow Transplantation|July 1, 1993
Treatment of life-threatening autoimmune diseases with myeloablative doses of immunosuppressive agents: experimental background and rationale for ABMTS SlavinPageof 991